Table 2.
Demographics and biomarkers of CSF samples used in study 4
| Study 4 | Controls (n = 42) | AD (n = 43) |
|---|---|---|
| Gender (male/female) | 1/3 | 1/3 |
| Age (years) | 72.64 [6.29] | 74.17 [7.71] |
| Clinical group, MMSE* | 29.24 [0.76] | 20.05 [4.31] |
| AD Biomarkers | ||
| Aβ40 [pg/ml] | 6690 [2139] | 6523 [1887] |
| Aβ42 [pg/ml] | 770.6 [303.2] | 409.6 [130.2] |
| t-Tau [pg/ml] | 365.3 [193.4] | 619.3 [200] |
| p-Tau [pg/ml] | 50.81 [35.26] | 116.4 [42.97] |
| Nlgn1signal ratio (F-7 ab) | 0.22 [0.11] | 0.17 [0.13] |
* Based on the Mini-Mental State Examination (MMSE) score, a score of 20 to 24 suggests mild cognitive impairment (MCI), 13 to 20 suggests moderate dementia and less than 12 indicates severe dementia
All the data are presented as mean and [standard deviation]